Aylin Pelin Cil1, Alev Leventoğlu2, Murat Sönmezer3, Rabia Soylukoç4, Kutluk Oktay5. 1. Kırıkkale University School of Medicine, Department of Obstetrics and Gynecology, Kırıkkale, Turkey. 2. Ufuk University School of Medicine, Department of Neurology, Ankara, Turkey. 3. Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey. 4. Kırıkkale University School of Medicine, Department of Neurology, Kırıkkale, Turkey. 5. New York Medical College, Department of Obstetrics and Gynecology, Valhalla, Ny, and Institute For Fertility Preservation, Center For Human Reproduction, New York, Usa.
Abstract
OBJECTIVE: There is limited data about fertility in multiple sclerosis (MS) patients using immunomodulating drugs and no data exists regarding the ovarian reserve of these patients. Therefore, we aimed to evaluate, the ovarian reserve and doppler characteristics of MS patients using immunomodulating drugs. MATERIAL AND METHODS: MS patients using immunomodulating drugs (interferon (IFN) β and glatiramer acetate) and age-matched healthy controls were included in the study. Subjects were examined in the early follicular phase of the menstrual cycle with transvaginal ultrasound to evaluate ovarian volume, antral follicle count (AFC) and ovarian stromal artery Doppler. On the same day, blood was taken for determining serum follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. A subgroup analysis was also carried out between MS patients using only IFN β and controls to compare the same parameters. RESULTS: Mean ovarian volume and total AFC were lower in MS patients using immunomodulating drugs than in the controls. FSH and E2 levels did not show any differences between the groups, but LH levels were significantly higher in MS patients. All the Doppler parameters of the ovarian stromal artery were higher in MS patients but not significantly. In the subgroup analysis, the same significant differences were found for ovarian volume, AFC and LH levels. In addition, MS patients showed significantly higher mean pulsatility index measurement than the controls. CONCLUSION: The findings of this study demonstrated diminished ovarian volume and follicular reserve in MS patients using immunomodulating drugs compared to age matched healthy controls. However, further studies are required to elucidate whether compromised ovarian reserve in MS patients is due to drugs or the disease itself.
OBJECTIVE: There is limited data about fertility in multiple sclerosis (MS) patients using immunomodulating drugs and no data exists regarding the ovarian reserve of these patients. Therefore, we aimed to evaluate, the ovarian reserve and doppler characteristics of MSpatients using immunomodulating drugs. MATERIAL AND METHODS:MSpatients using immunomodulating drugs (interferon (IFN) β and glatiramer acetate) and age-matched healthy controls were included in the study. Subjects were examined in the early follicular phase of the menstrual cycle with transvaginal ultrasound to evaluate ovarian volume, antral follicle count (AFC) and ovarian stromal artery Doppler. On the same day, blood was taken for determining serum follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. A subgroup analysis was also carried out between MSpatients using only IFN β and controls to compare the same parameters. RESULTS: Mean ovarian volume and total AFC were lower in MSpatients using immunomodulating drugs than in the controls. FSH and E2 levels did not show any differences between the groups, but LH levels were significantly higher in MSpatients. All the Doppler parameters of the ovarian stromal artery were higher in MSpatients but not significantly. In the subgroup analysis, the same significant differences were found for ovarian volume, AFC and LH levels. In addition, MSpatients showed significantly higher mean pulsatility index measurement than the controls. CONCLUSION: The findings of this study demonstrated diminished ovarian volume and follicular reserve in MSpatients using immunomodulating drugs compared to age matched healthy controls. However, further studies are required to elucidate whether compromised ovarian reserve in MSpatients is due to drugs or the disease itself.
Authors: G J Scheffer; F J M Broekmans; C W N Looman; M Blankenstein; B C J M Fauser; F H teJong; E R teVelde Journal: Hum Reprod Date: 2003-04 Impact factor: 6.918
Authors: I A J van Rooij; F J M Broekmans; E R te Velde; B C J M Fauser; L F J M M Bancsi; F H de Jong; A P N Themmen Journal: Hum Reprod Date: 2002-12 Impact factor: 6.918
Authors: M S Freedman; L D Blumhardt; B Brochet; G Comi; J H Noseworthy; M Sandberg-Wollheim; Sørensen P Soelberg Journal: Mult Scler Date: 2002-02 Impact factor: 6.312
Authors: O Andersen; I Elovaara; M Färkkilä; H J Hansen; S I Mellgren; K-M Myhr; M Sandberg-Wollheim; P Soelberg Sørensen Journal: J Neurol Neurosurg Psychiatry Date: 2004-05 Impact factor: 10.154